[1] |
Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features[J]. J Am Acad Dermatol, 2020,83(6):1559⁃1565. doi: 10.1016/j.jaad.2020.04.183.
|
[2] |
Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo[J]. J Eur Acad Dermatol Venereol, 2018,32(7):1059⁃1065. doi: 10.1111/jdv.14570.
|
[3] |
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non⁃atopic diseases: aetiological survey in a consecutive cohort of 108 patients[J]. J Eur Acad Dermatol Venereol, 2013,27(5):550⁃557. doi: 10.1111/j.1468⁃3083.2012. 04481.x.
|
[4] |
Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early⁃onset atopic and late⁃onset non⁃atopic[J]. Dermatology, 1995,190(4):269⁃276. doi: 10. 1159/000246715.
|
[5] |
Pugliarello S, Cozzi A, Gisondi P, et al. Phenotypes of atopic dermatitis[J]. J Dtsch Dermatol Ges, 2011,9(1):12⁃20. doi: 10.1111/j.1610⁃0387.2010.07508.x.
|
[6] |
Werfel T, Schwerk N, Hansen G, et al. The diagnosis and graded therapy of atopic dermatitis[J]. Dtsch Arztebl Int, 2014,111(29⁃30):509⁃520. doi: 10.3238/arztebl.2014.0509.
|
[7] |
Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta⁃analysis of the regional and age⁃related differences in atopic dermatitis clinical characteristics[J]. J Am Acad Dermatol, 2019,80(2):390⁃401. doi: 10.1016/j.jaad.2018.09.035.
|
[8] |
Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J]. Chin Med J (Engl), 2016,129(7):757⁃762. doi: 10.4103/0366⁃6999.178960.
|
[9] |
高子蕊, 赵培, 窦沅青, 等. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022,55(7):562⁃565. doi: 10.35541/cjd.20220077.
|
[10] |
Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis[J]. Dermatitis, 2020,31(1):81⁃84. doi: 10.1097/DER.0000000000000517.
|
[11] |
Mollanazar NK, Elgash M, Weaver L, et al. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis[J]. JAMA Dermatol, 2019,155(1):121⁃122. doi: 10. 1001/jamadermatol.2018.3906.
|
[12] |
Huang AH, Canner JK, Khanna R, et al. Real⁃world prevalence of prurigo nodularis and burden of associated diseases[J]. J Invest Dermatol, 2020,140(2):480⁃483.e4. doi: 10.1016/j.jid. 2019.07.697.
|
[13] |
张建中. 特应性皮炎的诊断标准发展及评价[J]. 中华皮肤科杂志, 2017,50(1):67⁃69. doi: 10.3760/cma.j.issn.0412⁃4030. 2017.01.025.
|
[14] |
Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China[J]. J Eur Acad Dermatol Venereol, 2020,34(3):542⁃548. doi: 10.1111/jdv.15979.
|
[15] |
Ständer S. Atopic dermatitis[J]. N Engl J Med, 2021,384(12):1136⁃1143. doi: 10.1056/NEJMra2023911.
|
[16] |
Fölster⁃Holst R, Reimer R, Neumann C, et al. Comparison of epidermal barrier integrity in adults with classic atopic dermatitis, atopic prurigo and non⁃atopic prurigo nodularis[J]. Biology (Basel), 2021,10(10):1008. doi: 10.3390/biology10101008.
|
[17] |
Shao Y, Zhu Y, Xiao Z, et al. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching[J]. Exp Dermatol, 2023,32(1):30⁃40. doi: 10.1111/exd.14678.
|
[18] |
Byun HJ, Jang D, Lee DY, et al. Immunohistochemical analysis of prurigo nodularis in 209 patients: clinicopathological analysis between atopic and non⁃atopic patients and between treatment response groups[J]. Ann Dermatol, 2021,33(4):333⁃338. doi: 10.5021/ad.2021.33.4.333.
|
[19] |
Feldmeyer L, Werner S, Kamarashev J, et al. Atopic prurigo nodularis responds to intravenous immunoglobulins[J]. Br J Dermatol, 2012,166(2):461⁃462. doi: 10.1111/j.1365⁃2133.2011. 10587.x.
|
[20] |
Kogawa K, Minakawa S, Matsuzaki Y, et al. Correlation between lactate dehydrogenase and other laboratory data in patients with atopic dermatitis[J]. J Cutan Immunol Allergy, 2022,5(4):133⁃135. doi: 10.1002/cia2.12225.
|
[21] |
Agelopoulos K, Renkhold L, Wiegmann H, et al. Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus[J]. J Invest Dermatol, 2023,143(2):264⁃272.e3. doi: 10.1016/j.jid. 2022.08.042.
|
[22] |
Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs[J]. Nat Rev Drug Discov, 2023,22(9):743⁃767. doi: 10.1038/s41573⁃ 023⁃00750⁃1.
|
[23] |
Georgakopoulos JR, Croitoru D, Felfeli T, et al. Long⁃term dupilumab treatment for chronic refractory generalized prurigo nodularis: a retrospective cohort study[J]. J Am Acad Dermatol, 2021,85(4):1049⁃1051. doi: 10.1016/j.jaad.2021.02.038.
|
[24] |
Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double⁃blind, placebo⁃controlled phase 3 trials[J]. Nat Med, 2023,29(5):1180⁃1190. doi: 10.1038/s41591⁃023⁃02320⁃9.
|
[25] |
Belzberg M, Alphonse MP, Brown I, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization[J]. J Invest Dermatol, 2021,141(9):2208⁃2218.e14. doi: 10.1016/j.jid.2021.02.749.
|
[26] |
Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo[J]. J Am Acad Dermatol, 2020,83(1):39⁃45. doi: 10.1016/j.jaad.2020.03.049.
|
[27] |
Wong LS, Yen YT, Lin SH, et al. IL⁃17A induces endothelin⁃1 expression through p38 pathway in prurigo nodularis[J]. J Invest Dermatol, 2020,140(3):702⁃706.e2. doi: 10.1016/j.jid. 2019.08.438.
|
[28] |
Park K, Mori T, Nakamura M, et al. Increased expression of mRNAs for IL⁃4, IL⁃17, IL⁃22 and IL⁃31 in skin lesions of subacute and chronic forms of prurigo[J]. Eur J Dermatol, 2011,21(1):135⁃136. doi: 10.1684/ejd.2010.1196.
|
[29] |
Gong F, Wu J, Zhou P, et al. Interleukin⁃22 might act as a double⁃edged sword in type 2 diabetes and coronary artery disease[J]. Mediators Inflamm, 2016,2016:8254797. doi: 10. 1155/2016/8254797.
|
[30] |
Tsoi LC, Hacini⁃Rachinel F, Fogel P, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab[J]. J Allergy Clin Immunol, 2022,149(4):1329⁃1339. doi: 10.1016/j.jaci.2021.10.004.
|
[31] |
Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin⁃31, oncostatin M, IL⁃31 receptor alpha and oncostatin M receptor beta[J]. Exp Dermatol, 2021,30(6):804⁃810. doi: 10.1111/exd. 14279.
|